1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Global Biologics Market: Size, Trends & Forecast (2018-2022)

Global Biologics Market: Size, Trends & Forecast (2018-2022)

  • February 2018
  • 91 pages
  • ID: 5336724
  • Format: PDF
  • By Daedal Research

Summary

Table of Contents

Search Inside

Scope of the Report
The report entitled “Global Biologics Market: Size, Trends & Forecast (2018-2022)”, provides an in-depth analysis of the global biologics market with description of market sizing and growth. The analysis includes market by value, by segment and by region. It also provides a detailed analysis of biologics market in terms of manufacturing process, product-category and therapeutic areas as well.

The report includes a brief regional analysis of North America, Europe and China with their actual and forecasted market size. North America has the largest stake in the global biologics market over the years and is expected to maintain its position in the upcoming years also. Among the Asia countries, China is the largest market and has the potential to grow steadily over the forecasted period.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global biologics market has also been forecasted for the years 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Abbvie Inc., Samsung Electronics (Samsung Biologics), F. Hoffmann La Roche and Amgen Inc. are some of the key players operating in the global biologics market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the respective companies are provided.

Company Coverage
Abbvie Inc.
Samsung Electronics (Samsung Biologics)
F. Hoffmann La Roche
Amgen Inc.

Regional Coverage
North America
Europe
China

Executive Summary
Pharmaceutical industry is engaged in the discovery, manufacturing and marketing of pharmaceutical drugs such as legal drugs, vaccines, biologics and a large number of medical devices such as infusion pump, pacemakers, prosthetics, implantable defibrillators etc.

Pharmaceutical drugs and devices are subjected to various laws and regulations governing their patent, safety, and efficacy. On an elementary level pharmaceutical drugs are broadly classified into two categories: small molecules (non-biologics) and large molecules (biologics).

Large molecules are mostly made of cells or other living organisms and are used to produce therapeutic proteins or biological molecules. Drugs made up of large molecules are popularly known as biotech drugs, biologics or biopharmaceuticals. The major biologics blockbusters currently available in the market are Humira, Remicade, Enbrel, Avastin and Herceptin.

The global biologics market has increased over the years and projections are made that the market would grow at a steady pace in the next four years i.e. 2018-2022, particularly due to increasing biologics approval and growing incidence of chronic conditions among the aging population.

The global biologics market is supported by various growth drivers such as increased availability of advanced diagnostics, raising auto-immune diseases, higher usage of monoclonal antibodies for the treatment of different diseases, advancement in healthcare & biotechnology, etc.

Yet the market faces some challenges which are obstructing the growth of the market. Some of the major challenges faced by the industry are: high cost of biologics, lack of oral absorption, complex regulatory approval etc.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2019

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2019, provides ...

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis) ...

T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019

T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019

  • $ 3500
  • November 2019

T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019SummaryT Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) pipeline Target constitutes ...


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on